Back to Search
Start Over
Eudragit ® -based microcapsules of probucol with a gut-bacterial processed secondary bile acid
- Source :
- Therapeutic Delivery
-
Abstract
- Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB). Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties. Results: Rheological properties and size distribution were similar among all groups. β-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups. Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules.
- Subjects :
- chemistry.chemical_classification
Chromatography
Bile acid
medicine.drug_class
Deoxycholic acid
Probucol
Pharmaceutical Science
02 engineering and technology
Polymer
021001 nanoscience & nanotechnology
030226 pharmacology & pharmacy
Formulation stability
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
medicine
Gliclazide
Absorption (chemistry)
0210 nano-technology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20416008 and 20415990
- Volume :
- 9
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Therapeutic Delivery
- Accession number :
- edsair.doi.dedup.....23e95f7c989e9e24d45dbaf096a456ac
- Full Text :
- https://doi.org/10.4155/tde-2018-0036